# "The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors"

> **NCT05355597** · PHASE2 · TERMINATED · sponsor: **Atlantic Health System** · enrollment: 116 (actual)

## Conditions studied

- Musculoskeletal Diseases
- Soft Tissue Mass

## Interventions

- **DRUG:** Exparel Injectable Product
- **DRUG:** Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)

## Key facts

- **NCT ID:** NCT05355597
- **Lead sponsor:** Atlantic Health System
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-01-27
- **Primary completion:** 2025-03-24
- **Final completion:** 2025-03-24
- **Target enrollment:** 116 (ACTUAL)
- **Why stopped:** Physician left institution
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05355597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05355597, ""The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors"". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05355597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*